Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.58 - $5.05
Previous CloseN/A
Volume4.05K
Average Volume (3M)45.88K
Market Cap
$193.81M
Enterprise Value-$12.52M
Total Cash (Recent Filing)$68.53M
Total Debt (Recent Filing)$30.13M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 12, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding66,831,070
10 Day Avg. Volume93,952
30 Day Avg. Volume45,883
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)48.09
Price to Sales (P/S)0.00
P/FCF Ratio-30.83
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.27
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$5.75Price Target Upside100.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
SOPHiA GENETICS News
PremiumCompany Announcements
SOPHiA GENETICS Releases 2024 ESG Impact Summary
PremiumCompany Announcements
SOPHiA GENETICS Q1 2025 Earnings Call Highlights
PremiumCompany Announcements
SOPHiA GENETICS to Hold Annual General Meeting Amidst Strategic Growth
PremiumCompany Announcements
SOPHiA GENETICS Reports Strong Q1 2025 Growth
PremiumCompany Announcements
SOPHiA GENETICS Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Customer GrowthThe company signed 28 new customers in the first quarter and implemented 33 new customers, which is a positive leading indicator for growth.
Future GrowthSOPH guided for a return to double-digit revenue growth in 2025 as the company is confident in its ability to turn on customers new to SOPH's DDM platform, particularly for the newer MSK-Access liquid biopsy application.
Market ExpansionManagement believes revenue re-acceleration will continue as key growth drivers take effect, including new customer additions and US market expansion.
Bears Say
Biopharma RevenueThe company faced several headwinds in 2024 resulting in below long-term trend growth, notably from a lower biopharma revenue ramp and disruptions in LATAM.
Customer ChurnSOPH added 35 new genomics customers to Sophia DDM in Q4, which was solid, partially offset by a ~4% smaller customer churn.
Revenue ChallengesSophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.08% Mutual Funds
19.84% Other Institutional Investors
79.01% Public Companies and Individual Investors
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.58 and its highest was $5.05 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $193.81M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 12, 2025 which is in 58 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.22.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 66,831,070 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.75 (100.35% Upside)
$5.75 (100.35% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.70%
12-Months-Change
Fundamentals
Return on Equity
-60.75%
Trailing 12-Months
Asset Growth
-18.61%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS (SOPH) is a health technology company that leverages data-driven medicine to enhance and expedite the analysis of genomic and radiomic data. The company operates within the biotechnology and healthcare sectors, providing a cloud-based software platform that enables healthcare institutions to analyze complex medical data to deliver insights that can improve patient outcomes. SOPHiA GENETICS' core product, the SOPHiA DDM™ platform, is designed to facilitate the interpretation of genomic data, thereby supporting various applications in oncology, rare diseases, and other health conditions.
SOPH Company Deck
SOPH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
SOPHiA GENETICS demonstrated strong revenue growth and customer expansion, particularly in the U.S. market, alongside successful cost management and strategic partnerships. However, challenges in Latin America and the biopharma segment presented some headwinds.Read More>SOPH Stock 12 Month Forecast
Average Price Target
$5.75
▲(100.35%Upside)